CoChat

Hypoxia-Inducible Factor 2α: A Novel Target in Gliomas

Open access

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Abstract

Hypoxia is an important contributor to aggressive behavior and resistance mechanisms in glioblastoma. Upregulation of hypoxia inducible transcription factors (HIFs) is the primary adaptive cellular response to a hypoxic environment. While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival. A first-in-class HIF2α inhibitor, PT2385, is in clinical trials for renal cell carcinoma, and provides the first opportunity to therapeutically target this important pathway in glioma biology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4155/fmc-2018-0163

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

4 retracted

Show all 85 references

Research works printed but not linked: 2

  1. 10.1128/mcb.12.12.5447-5454.1992 · doi:10.1128/mcb.12.12.5447-5454.1992 · Paper page
  2. Wallace E . PT2385: HIF-2a antagonist for the treatment of VHL mutant ccRCC. Proceedings of : 12th International VHL Medical Symposium. MA, USA, 7–9 April 2016 .

Cited by

See all 40

Metadata

Authors
Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E.
Affiliations
  • Atrium Health Wake Forest Baptist (US)
  • Mayo Clinic (US)
  • Brain Tumor Center of Excellence Wake Forest Comprehensive Cancer Center Winston-Salem NC 27157 USA
Venue
Future Medicinal Chemistry
Published
2018-08-09
Volume
10
Issue
18
Pages
2227-2236
ISSN
  • 1756-8919 (ISSN-L)
  • 1756-8927
OpenAlex
W2886561153
Cited by
40
References
85
Citations by year
2026: 2 · 2025: 7 · 2024: 2 · 2023: 4 · 2022: 7 · 2021: 6 · 2020: 10 · 2019: 1 · 2018: 1
FWCI
0.47
Type
journal article
Language
en
Open access
Locations
  • Future Medicinal Chemistry (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (P30CA012197)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
HIF-2α, glioblastoma, glioma stem cells, tumor hypoxia, PT2385, targeted cancer therapy, drug resistance
MeSH terms
Endothelial PAS Domain-Containing Protein 1, Glioma, Humans, Indans, Sulfones, RNA Interference, RNA, Small Interfering, Basic Helix-Loop-Helix Proteins, Von Hippel-Lindau Tumor Suppressor Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hypoxia-Inducible Factor 2α: A Novel Target in Gliomas. https://app.cochat.ai/papers/10.4155/fmc-2018-0163
The paper
Renfrow, J. J., Soike, M. H., Debinski, W., Ramkissoon, S. H., Mott, R. T., Frenkel, M. B., Sarkaria, J. N., Lesser, G. J., & Strowd, R. E. (2018). Hypoxia-Inducible Factor 2α: A Novel Target in Gliomas. Future Medicinal Chemistry. https://doi.org/10.4155/fmc-2018-0163

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.